Calidi Biotherapeutics, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
2.08M
on 2026-06-30, from 19K on 2024-03-31 10-Q ↗
Earlier counts are adjusted for three reverse splits; each bar's tip shows the count as filed.
a raise that quarter, at its price
$6.1M
Ladenburg Thalmann, agreement of 2025-02-05. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗
Warrants
3,640
Warrants of every class as tagged in the XBRL facts on 2024-07-26, exercise price $30.40. Adjusted for the 1-for-16 reverse split. 10-Q ↗
Cash
1 quarters
$4.3M on 2026-06-30 ÷ $4.4M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-09-17 | Public offering | 1,025,640 | $1.17 | $1.2M | 424B5 ↗ |
| 2026-03-06 | Public offering | not read | not read | $5.3M | 424B5 ↗ |
| 2025-08-20 | Public offering with warrants at $2.00 | not read | $2.00 | $6.0M | 424B4 ↗ |
| 2025-07-09 | Private placement | 6,595,000 | not read | $4.6M | 8-K ↗ |
| 2025-03-28 | Public offering incl. 2.73M pre-funded | 6,053,000 | $0.65 | $3.9M | 424B5 ↗ |
| 2025-01-09 | Public offering | 5,000,000 | $0.85 | $4.3M | 424B5 ↗ |